- The Wall Street Journal•2 hours ago
After operating in stealth for about four years while studying ways to turn back the clock on diseases of aging in animals, now it has fresh capital to do the same thing in humans.
- Zacks•4 hours ago
Allergan plc (AGN) will be reporting third-quarter 2016 earnings on Nov 2, before market open. Last quarter, the company delivered a positive earnings surprise of 2.13%.
- American City Business Journals•5 hours ago
Allergan has announced it will acquire Boston-based Motus Therapeutics for $200 million. Motus, a wholly-owned subsidiary of Rhythm Holding Co. which also owns Rhythm Pharmaceuticals, is focused on developing peptide therapeutics for gastrointestinal disease. Allergan (AGN) previously paid $47 million for the option to acquire Motus, funding that also went to support Phase 2b clinical trials.
Allergan plc (AGN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||221.71 x 200|
|Ask||221.80 x 300|
|Day's Range||220.38 - 224.91|
|52wk Range||195.50 - 322.68|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.10|
|Avg Vol (3m)||3,301,864|
|Dividend & Yield||N/A (N/A)|